Biotech

News

Acelyrin raises $540 million in rare biotech IPO

Biotech watchers lamenting a fall-off in public listings for biotech companies will take some heart from Acelyrin’s upsized initial public offering, which ended up at the

R&D

Is biotech ready for the lecanemab opportunity?

The US Veterans Health Administration recently announced that it will cover the cost of Biogen’s lecanemab for veterans suffering from early stages of Alzheimer’s disease.

News

Last year’s UK biotech financing dip extends into 2023

The first quarter of 2023 saw just £295 million raised by UK-based life sciences and biotech companies, signalling that investor confidence remains low after a disappointi

News

Regeneron chair Vagelos steps down at 93

Biopharma legend P. Roy Vagelos will step down as chairman of Regeneron Pharmaceuticals after 29 years in June, at the age of 93.

News

Complement raises €72m for geographic atrophy gene therapy

UK start-up Complement Therapeutics has raised an impressive €72 million ($79 million) in first-round financing that will be used to take a gene therapy for sight-robbing

R&D

The pharma trends leading to higher demand for CDMOs

Recent discoveries and advances in pharma for lower demand illnesses/indications have resulted in an increase in the number of smaller start-up organisations.

Acelyrin raises $540 million in rare biotech IPO

Is biotech ready for the lecanemab opportunity?

Last year’s UK biotech financing dip extends into 2023

Regeneron chair Vagelos steps down at 93

Complement raises €72m for geographic atrophy gene therapy

The pharma trends leading to higher demand for CDMOs

GBL joins CVC in €10.7bn takeover bid for Recordati

Discover a new era of healthcare panel engagement: Grounded ...

Biotech

Editor's Picks